# US 2025/0154533 A1 · Engineered retrons and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154533 A1
- Document ID: US20250154533A1
- Status: Published application
- Kind: A1
- Application number: 18/752,190
- Filed: 2024-06-24
- Published: 2025-05-15
- Earliest claimed: 2022-01-21
- Assignees: ReNAgade Therapeutics Management Inc.
- Applicants: ReNAgade Therapeutics Management Inc.
- Inventors: Alim Ladha; Vladimir Presnyak; Inna Shcherbakova; Brian Goodman; Mario Rodriguez Mestre; Devin Scott Quinlan; Muthusamy Jayaraman; Stephen Scully
- Web page: https://patentgrep.com/patent/US20250154533A1

## CPC

- C12N 15/907: {in mammalian cells}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A gene editing system comprising one or more delivery vehicles, wherein:
the delivery vehicle(s) comprise RNA cargo,
said RNA cargo comprises (a) at least one mRNA molecule encoding (i) a nucleic acid programmable nuclease and (ii) a retron reverse transcriptase, (b) an engineered retron ncRNA, and (c) guide RNA for the nucleic acid programmable nuclease;
wherein the engineered retron ncRNA comprises an HDR nucleotide sequence substituted into a retron ncRNA;
wherein the retron ncRNA nucleotide sequence has about 85% to 98% sequence identity to any one of SEQ ID NO:14826, SEQ ID NO: 17305, or SEQ ID NO:18409;
wherein the HDR nucleotide sequence is substituted at a hairpin loop of the retron ncRNA;
wherein the retron reverse transcriptase and the retron ncRNA are from the same phylogenetic clade;
each delivery vehicle contains (a)(i) and/or (a)(ii) and/or (b) and/or (c),
whereby one delivery vehicle or more than one delivery vehicle delivers (a)(i), (a)(ii), (b), and (c).

### Claim 32 (depends on 31)

The gene editing system of claim 31, wherein the retron ncRNA nucleotide sequence has at least about 85% to 98% sequence identity to SEQ ID NO:14826, and the retron reverse transcriptase comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 627-645, 650-659, 693-694, 744, 768-769, 1451, 1455, 1467-1468, 1527-1528, 1570, 1578, 1579, 1604-1611, 2429-2444, 2583-2591, 2596-2597, 2867-2886, 4876-4883, 5144-5146, 5152-5176, 5193-5194, 6666-6680, 6695-6696, 6702-6787, 6804-6822, 6973, 7050-7053, and 7134-7257.

### Claim 33 (depends on 32)

The gene editing system of claim 32, wherein the retron reverse transcriptase comprises an amino acid sequence at least about 90% identical to SEQ ID NO:637.

### Claim 34 (depends on 31)

The gene editing system of claim 31, wherein the retron ncRNA nucleotide sequence has about 85% to 98% sequence identity to SEQ ID NO: 17305, and the retron reverse transcriptase comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs:4179-4670 and 4884-4909.

### Claim 35 (depends on 34)

The gene editing system of claim 34, wherein the retron reverse transcriptase comprises an amino acid sequence at least about 90% identical to SEQ ID NO:4438.

### Claim 36 (depends on 31)

The gene editing system of claim 31, wherein the retron ncRNA nucleotide sequence has about 85% to 98% sequence identity to SEQ ID NO:18409, and the retron reverse transcriptase comprises an amino acid sequence at least 90% identical to any one of SEQ ID NO:5195 to SEQ ID NO:5941.

### Claim 37 (depends on 36)

The gene editing system of claim 36, wherein the retron reverse transcriptase comprises an amino acid sequence at least 90% identical to SEQ ID NO:5923.

### Claim 38 (depends on 31)

The gene editing system of claim 31, wherein (a)(i) and (a)(ii) comprise a single mRNA molecule encoding the nucleic acid programmable nuclease and the retron reverse transcriptase.

### Claim 39 (depends on 38)

The gene editing system of claim 38, wherein (a)(i) and (a)(ii) are encoded and expressed as a fusion protein.

### Claim 40 (depends on 39)

The gene editing system of claim 39, wherein the fusion protein comprises the C-terminal end of the nucleic acid programmable nuclease fused to the N-terminal end of the retron reverse transcriptase (nuclease:RT fusion).

### Claim 41 (depends on 39)

The gene editing system of claim 39, wherein the fusion protein comprises the N-terminal end of the nucleic acid programmable nuclease fused to the C-terminal end of the retron reverse transcriptase (RT:nuclease fusion).

### Claim 42 (depends on 31)

The gene editing system of claim 31, wherein (a)(i) and (a)(ii) comprise a first mRNA molecule encoding the nucleic acid programmable nuclease and a second mRNA molecule encoding the retron reverse transcriptase.

### Claim 43 (depends on 31)

The gene editing system of claim 31, wherein (c) is separate from (a)(i), (a)(ii) and (b) or is provided in trans.

### Claim 44 (depends on 31)

The gene editing system of claim 31, wherein (b) the engineered retron ncRNA, and (c) the guide RNA are fused or are provided in cis.

### Claim 45 (depends on 44)

The gene editing system of claim 44, wherein the engineered ncRNA comprises a first guide RNA fused to the 5′ end of the retron ncRNA, and a second guide RNA fused to the 3′ end of the retron ncRNA, and the first and second guide RNAs target different sequences.

### Claim 46 (depends on 31)

The gene editing system of claim 31, wherein (a) the at least one mRNA molecule encoding (i) the nucleic acid programmable nuclease and (ii) the retron reverse transcriptase, and (b) the engineered retron ncRNA are in the same delivery vehicle.

### Claim 47 (depends on 31)

The gene editing system of claim 31, wherein the HDR nucleotide sequence encodes a donor polynucleotide comprising an intended edit to be integrated at a target sequence in a cell, and wherein the donor polynucleotide is flanked by a 5′ homology arm that hybridizes to a sequence 5′ to the target sequence and a 3′ homology arm that hybridizes to a sequence 3′ to the target sequence.

### Claim 48 (depends on 31)

The gene editing system of claim 31, wherein the nucleic acid programmable nuclease comprises a Cas9 nuclease, a TnpB nuclease, or a Cas12a nuclease.

### Claim 49 (depends on 31)

The gene editing system of claim 31, wherein the nucleic acid programmable nuclease comprises a Cas9 nuclease.

### Claim 50 (depends on 31)

The gene editing system of claim 31, wherein the engineered retron ncRNA comprises:
A) a pre-msr sequence having a first complementary region of the retron ncRNA;
B) an msr sequence including an msr stem-loop structure;
C) an msd sequence including an msd stein-loop structure and comprising the HDR nucleotide sequence, wherein said msd sequence templates a single strand DNA product (RT-DNA) in the presence of the retron reverse transcriptase; and
D) a post-msd sequence having a second complementary region.

### Claim 51 (depends on 50)

The gene editing system of claim 50, wherein the HDR nucleotide sequence encodes a donor polynucleotide comprising an intended edit to be integrated at a target sequence of a cell, wherein the donor polynucleotide is flanked by a 5′ homology arm that hybridizes to a sequence 5′ to the target sequence and a 3′ homology arm that hybridizes to a sequence 3′ to the target sequence.

### Claim 52 (depends on 31)

An isolated cell comprising the gene editing system of claim 31.

### Claim 53 (depends on 52)

The isolated cell of claim 52, wherein the isolated cell is a mammalian cell.

### Claim 54 (depends on 53)

The isolated cell of claim 53, wherein the mammalian cell is a human cell.

### Claim 55 (depends on 31)

A composition comprising:
a) the gene editing system of claim 31; and
b) a pharmaceutically or veterinarily acceptable carrier.

### Claim 56 (depends on 55)

The composition of claim 55, wherein the delivery vehicle is a lipid nanoparticle comprising:
a) one or more ionizable lipids;
b) one or more structural lipids;
c) one or more PEGylated lipids; and
d) one or more phospholipids.

### Claim 57 (depends on 47)

A method of genetically modifying a cell comprising:
contacting the gene editing system of claim 47 with the cell, thereby delivering the RNA cargo to the cell,
wherein:
the nucleic acid programmable nuclease forms a complex with the guide RNA, wherein said guide RNA directs the complex to the target sequence,
the nucleic acid programmable nuclease creates a double-stranded break in the target sequence,
the retron reverse transcriptase and engineered retron ncRNA create RT DNA that comprises the donor polynucleotide, and
the donor polynucleotide becomes integrated at the target sequence.
